Atlas Venture Funds File Intent to Sell $3.36M in Dyne Therapeutics Stock Amid Ongoing Distribution
DYN has more than doubled off its 52-week low of $8.06 on elevated volume (3.1× avg).
Summary
A major institutional shareholder, Atlas Venture Fund XI, LP, intends to sell an additional $3.36 million of Dyne Therapeutics stock, continuing a trend of significant distribution by the fund and other insiders.
Key Events · Ownership and Investor Activity · DYN
-
Intent to Sell Additional Shares
Atlas Venture Fund XI, LP, a shareholder, filed a Form 144 to sell 162,954 shares of common stock, valued at approximately $3.36 million.
-
Ongoing Institutional Distribution
This proposed sale follows over $18.9 million in sales by Atlas Venture Fund XI, LP in the past three months, indicating a sustained reduction in its stake.
-
Contributes to Broader Insider Selling
The sales by Atlas Venture are part of a larger trend of insider distribution at Dyne Therapeutics, with net insider sales exceeding $51 million over the last 90 days.
Analysis · DYN · Life Sciences
Atlas Venture Fund XI, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $3.36 million worth of Dyne Therapeutics common stock. This proposed sale is part of an ongoing pattern of distribution by Atlas Venture funds, which have sold over $18.9 million in Dyne Therapeutics shares in the past three months, contributing to a broader insider selling trend totaling over $51 million. This continued selling by a major investor could signal a reduction in conviction.
At the time of this filing, DYN was trading at $20.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.